Literature DB >> 23110735

Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients.

Tammon Nash, Sandra Hoffmann, Suzanne Butch, Robertson Davenport, Laura Cooling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23110735     DOI： 10.1111/j.1537-2995.2012.03739.x

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  4 in total

Review 1.  Leucoreduction of blood components: an effective way to increase blood safety?

Authors:  Maria Bianchi; Stefania Vaglio; Simonetta Pupella; Giuseppe Marano; Giuseppina Facco; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-12-16       Impact factor: 3.443

Review 2.  Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?

Authors:  Malte Ziemann; Holger Hennig
Journal:  Transfus Med Hemother       Date:  2013-12-19       Impact factor: 3.747

3.  Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.

Authors:  Sophie Voruz; Peter Gowland; Claudia Eyer; Nadja Widmer; Mélanie Abonnenc; Michel Prudent; Stavroula Masouridi-Levrat; Michel A Duchosal; Christoph Niederhauser
Journal:  Blood Transfus       Date:  2020-02-28       Impact factor: 3.443

Review 4.  Transfusion in Neonatal Patients: Review of Evidence-Based Guidelines.

Authors:  Patricia E Zerra; Cassandra D Josephson
Journal:  Clin Lab Med       Date:  2020-12-23       Impact factor: 2.172
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.